Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 4.85 CHF 0.73% Market Closed
Market Cap: 178.8m CHF
Have any thoughts about
Molecular Partners AG?
Write Note

Intrinsic Value

MOLN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one MOLN stock under the Base Case scenario is 3.07 CHF. Compared to the current market price of 4.85 CHF, Molecular Partners AG is Overvalued by 37%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MOLN Intrinsic Value
3.07 CHF
Overvaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Molecular Partners AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MOLN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MOLN?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Molecular Partners AG

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Molecular Partners AG

Provide an overview of the primary business activities
of Molecular Partners AG.

What unique competitive advantages
does Molecular Partners AG hold over its rivals?

What risks and challenges
does Molecular Partners AG face in the near future?

Has there been any significant insider trading activity
in Molecular Partners AG recently?

Summarize the latest earnings call
of Molecular Partners AG.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Molecular Partners AG.

Provide P/S
for Molecular Partners AG.

Provide P/E
for Molecular Partners AG.

Provide P/OCF
for Molecular Partners AG.

Provide P/FCFE
for Molecular Partners AG.

Provide P/B
for Molecular Partners AG.

Provide EV/S
for Molecular Partners AG.

Provide EV/GP
for Molecular Partners AG.

Provide EV/EBITDA
for Molecular Partners AG.

Provide EV/EBIT
for Molecular Partners AG.

Provide EV/OCF
for Molecular Partners AG.

Provide EV/FCFF
for Molecular Partners AG.

Provide EV/IC
for Molecular Partners AG.

Show me price targets
for Molecular Partners AG made by professional analysts.

What are the Revenue projections
for Molecular Partners AG?

How accurate were the past Revenue estimates
for Molecular Partners AG?

What are the Net Income projections
for Molecular Partners AG?

How accurate were the past Net Income estimates
for Molecular Partners AG?

What are the EPS projections
for Molecular Partners AG?

How accurate were the past EPS estimates
for Molecular Partners AG?

What are the EBIT projections
for Molecular Partners AG?

How accurate were the past EBIT estimates
for Molecular Partners AG?

Compare the revenue forecasts
for Molecular Partners AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Molecular Partners AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Molecular Partners AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Molecular Partners AG compared to its peers.

Compare the P/E ratios
of Molecular Partners AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Molecular Partners AG with its peers.

Analyze the financial leverage
of Molecular Partners AG compared to its main competitors.

Show all profitability ratios
for Molecular Partners AG.

Provide ROE
for Molecular Partners AG.

Provide ROA
for Molecular Partners AG.

Provide ROIC
for Molecular Partners AG.

Provide ROCE
for Molecular Partners AG.

Provide Gross Margin
for Molecular Partners AG.

Provide Operating Margin
for Molecular Partners AG.

Provide Net Margin
for Molecular Partners AG.

Provide FCF Margin
for Molecular Partners AG.

Show all solvency ratios
for Molecular Partners AG.

Provide D/E Ratio
for Molecular Partners AG.

Provide D/A Ratio
for Molecular Partners AG.

Provide Interest Coverage Ratio
for Molecular Partners AG.

Provide Altman Z-Score Ratio
for Molecular Partners AG.

Provide Quick Ratio
for Molecular Partners AG.

Provide Current Ratio
for Molecular Partners AG.

Provide Cash Ratio
for Molecular Partners AG.

What is the historical Revenue growth
over the last 5 years for Molecular Partners AG?

What is the historical Net Income growth
over the last 5 years for Molecular Partners AG?

What is the current Free Cash Flow
of Molecular Partners AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Molecular Partners AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Molecular Partners AG

Current Assets 165.6m
Cash & Short-Term Investments 159.1m
Receivables 3.4m
Other Current Assets 3.1m
Non-Current Assets 5m
PP&E 4.9m
Intangibles 122k
Current Liabilities 11.4m
Accounts Payable 2.9m
Accrued Liabilities 6.7m
Other Current Liabilities 1.8m
Non-Current Liabilities 3.7m
Long-Term Debt 1.8m
Other Non-Current Liabilities 1.9m
Efficiency

Earnings Waterfall
Molecular Partners AG

Revenue
10.4m CHF
Operating Expenses
-85.9m CHF
Operating Income
-75.5m CHF
Other Expenses
6.4m CHF
Net Income
-69.1m CHF

Free Cash Flow Analysis
Molecular Partners AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MOLN Profitability Score
Profitability Due Diligence

Molecular Partners AG's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROE is Increasing
Positive 3-Years Revenue Growth
Negative 1-Year Revenue Growth
30/100
Profitability
Score

Molecular Partners AG's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

MOLN Solvency Score
Solvency Due Diligence

Molecular Partners AG's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Molecular Partners AG's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MOLN Price Targets Summary
Molecular Partners AG

Wall Street analysts forecast MOLN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MOLN is 11.22 CHF with a low forecast of 7.07 CHF and a high forecast of 15.75 CHF.

Lowest
Price Target
7.07 CHF
46% Upside
Average
Price Target
11.22 CHF
131% Upside
Highest
Price Target
15.75 CHF
225% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MOLN?

Click here to dive deeper.

Dividends

Molecular Partners AG
does not pay dividends
Shareholder Yield

Current shareholder yield for MOLN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MOLN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

MOLN News

Other Videos

Profile

Molecular Partners AG Logo
Molecular Partners AG

Country

Switzerland

Industry

Biotechnology

Market Cap

177.5m CHF

Dividend Yield

0%

Description

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Contact

ZUERICH
Schlieren
Wagistrasse 14
+41447557700.0
www.molecularpartners.com

IPO

2014-10-22

Employees

163

Officers

Co-Founder, CEO, Member of Management Board & Director
Dr. Patrick Amstutz Ph.D.
Co-Founder, Executive VP of Projects & Member of Management Board
Dr. Michael Tobias Stumpp Ph.D.
Senior VP of Finance
Mr. Robert Hendriks
COO & Member of Management Board
Mr. Alexander Zurcher
Executive VP of People & Community and Member of Management Board
Ms. Renate Gloggner
Senior Vice President of Research & Technology
Mr. Daniel Steiner Ph.D.
Show More
Senior Vice President of Investor Relations, Communications & Strategy
Mr. Seth D. Lewis
General Counsel, Compliance Officer, Senior VP Legal & Business Development
Mr. Michael Pitzner
Strategic Consultant
Dr. Pamela A. Trail Ph.D.
Senior Vice President of Research & Early Development
Ms. Anne Goubier D.V.M., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MOLN stock?

The intrinsic value of one MOLN stock under the Base Case scenario is 3.07 CHF.

Is MOLN stock undervalued or overvalued?

Compared to the current market price of 4.85 CHF, Molecular Partners AG is Overvalued by 37%.

Back to Top